Shanghai Haikang Pharmaceutical, located in the Shanghai International Medical Park, is a leading company in the field of traditional Chinese medicine and plant extracts. With a strong emphasis on research and development, the company has established a wholly-owned subsidiary, Shanghai Haikang Biopharmaceutical, which focuses on industrial-scale development of projects including new drug R&D, pilot production, and more. The company boasts a team of renowned professors and experts from the Chinese Academy of Medical Sciences' Cancer Research Institute, which has solidified their position as a highly competitive and rapidly growing enterprise.

Shanghai Haikang Pharmaceutical is currently dedicated to the development of two monoclonal antibodies, both innovative products with independent intellectual property rights. These groundbreaking projects have progressed to the clinical trial application phase and preclinical stage. Additionally, their expertise in a specialized technology platform ensures continuous support for the development of new drug products.

With a commitment to excellence, Shanghai Haikang Pharmaceutical aims to provide innovative and high-quality pharmaceutical solutions for the benefit of patients worldwide